HOME > BUSINESS > Zydus Cadila gets USFDA approval for generic form of colitis drug Lialda

Zydus Cadila gets USFDA approval for generic form of colitis drug Lialda

Zydus Cadila said the US Food and Drug Administration has given the final approval to market the company’s Mesalamine Delayed-Release Tablets in the US market.

Zydus Cadila was the first to file an Abbreviated New Drug Application (ANDA) for a generic version of Lialda.

Lialda is indicated for the treatment of mild to moderate ulcerative colitis.

Ulcerative colitis is a chronic inflammatory bowel disease that affects approximately 700,000 people in the United States.

The generic version of Lialda, called mesalamine, will be produced at the company’s Moraiya Plant located at Ahmedabad.

The estimated brand sales for Mesalamine Delayed-Release Tablets USP, 1.2 g is US $ 1.145 billion as per IMS MAT April 2017.

The group now has more than 115 approvals and has so far filed over 300 ANDAS since the commencement of the filing process in FY 2003-04.

Zydus Cadila employs over 20000 people worldwide.

Follow ULTRA.news
Glenmark launches anti-inflammation drug based on Adalimumab Glenmark enters Adalimumab market Glenmark Pharmaceuticals said it has launched a biosimilar of Adalimumab, a drug for Plaque Psoriasis and Rheumatoid Arthritis from Cadila Healthcare Ltd.. "The launch of ADALY marks the launch of Glenmark’s first biosimilar in Dermatology...
OrbiMed Asia invests $7.5 mln more in Vivimed Labs unit Vivimed Labs said it will receive $7.5mn investment from OrbiMed Asia into its API business as a follow on to the $42.5 mn invested in September 2017. At the time, Vivimed has said that the proceeds will be utilised for debt reduction at the parent entity level as well as for...
Lupin gets USFDA nod for scalp solution Pharma Major Lupin announced that it has received final approval from the US Food & Drug Administration to market a generic version of Dovonex Scalp Solution from Leo Pharmaceutical Products Ltd. Calcipotriene Topical Solution is indicated for the topical treatment of chroni...
Aurobindo Pharma gets USFDA nod for generic deep vein thrombosis drug Aurobindo Pharma Limited said it received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Fondaparinux Sodium injection -- a bioequivalent and therapeutic equivalent to Arixtra of Mylan Ireland. The product, used to prevent deep vein th...
Sun Pharma’s eye drug application accepted by USFDA Sun Pharmaceutical Industries Ltd said the US FDA has accepted a New Drug Application (NDA) for its OTX-101 dry eye drug. The application will now be processed for approval. Dry eye is a condition in which the eye does not produce tears properly, or when the tears are not of t...
Suven gets neuro drug patents in India, Canada Suven Life Sciences Ltd said it has been granted one patent each in Canada and India for drugs for treating Neurodegenerative diseases. The Canadian patent 2932428 is valid through 2034 and the Indian patent 289123 is valid through 2028. The chemical entities are consider...
Lupin gets US approval for generic version of Bayer’s oral contraceptive Pharma Major Lupin said it got the approval of the US Food and Drug Administration to launch a generic version of Bayer's oral contraceptive Safyral. The branded version has annual sales of around $23 mln in the US. Lupin's product will be called Tydemy. The combination...
Glenmark reports successful trial for nasal spray, to file NDA soon Glenmark Pharmaceuticals, a global pharmaceutical company, today announced that its nasal spray Ryaltris met safety and efficacy goals in a Phase 3 clinical study in treating perennial allergic rhinitis. With the positive results, the company said it plans to submit an applica...
Neuland Laboratories acquires Hyderabad factory from Arch Pharma Pharma manufacturer Neuland Laboratories said it acquired a manufacturing plant located near Hyderabad from Arch Pharma Labs Limited. The facility is spread across 12 acres and has a capacity of about 197 KL, the company said. The plant was inspected by the USFDA in 2015, ...
Eris Lifesciences completes acquisition of Strides Shasun India generics ops Pharma company Eris LifeSciences said it has completed its purchase of the India branded generics of Strides Shasun for Rs 500 cr in cash. "We now wish to confirm that the transaction ahs achieved closure," said Eris Lifesciences. Last month, Strides Shasun said it was sel...
Crucial win for Biocon as FDA approves cancer biosimilar trastuzumab Biocon and its partner Mylan scored a key victory on Friday as the US Food & Drug Administration approved its cancer-treating biosimilar trastuzumab. "Mylan anticipates potentially being the first company to offer a biosimilar to Herceptin, as a result of Mylan's ability to s...
EU accepts Biocon, Mylan’s application for cancer biosimilar pegfilgrastim Indian pharma company Biocon and its partner Mylan said EU authorities have accepted for review their applications for approving cancer treating biosimilars trastuzumab and pegfilgrastim submitted after completing corrective actions. The applications were resubmitted last mo...
Dr Reddy’s says EU approves production at Duvvada plant in Andhra Pharma major Dr Reddy's Laboratories said European Union authorities have again allowed it to produce drugs for sale in the EU region at its Duvvada factory in Andhra Pradesh. In its inspection conducted in September, the Regulatory Authority of Germany (Regierun von Oberbayer...
Panacea Biotec gets US nod for generic version of cancer drug Abraxane Panacea Biotec said it got the regulatory nod in the US for launching a generic version of big-selling cancer drug Abraxane. The drug will be sold with the help of Canadian pharmaceutical distributor Apotex. The annual sale of Abraxane worldwide is approximately US$973.4 m...
ICMR, Zydus launch diagnostic kits for infectious diseases Government of India-funded Indian Council of Medical Research (ICMR) and private sector player Zydus have announced the launch of new diagnostic kits that can help in detecting Japanese Encephalitis Virus in mosquitoes and the Crimean-Congo Haemorrhagic Fever in sheep, goat and ...
Dr Reddy’s gets served with class action lawsuit Pharma major Dr Reddy's Laboratories said it has been served with a class action lawsuit, originally announced in August, related to public disclosures made about regulatory action against the company. "Further to our intimation dated August 28, 2017 with regard to US Securit...
Zydus Cadila gets USFDA nod to launch generic version of billion-dollar drug Cialis eventually The United States Food and Drug Administration has given Zydus Cadila approval to launch a generic version of the billion-dollar erectile dysfunction drug Cialis when patents expire. The patents are expected to expire in September next year. Cialis and Viagra are the most ...
Glenmark Pharma to launch birth control pill in USA Glenmark Pharmaceuticals said it got the approval of the United States Food & Drug Administration to launch a generic version of birth control pill Loestrin from Allergan Pharmaceuticals International. The drug had annual sales of approximately $116.8 million. The drug Nor...
Strides Shasun gets USFDA nod to launch nausea drug Strides Shasun Limited said it received approval from the United States Food & Drug Administration (USFDA) to launch a generic version of Diamox Tablets. The primary use of the Acetazolamide is to reduce nausea and dizziness associated with altitude sickness, but the drug is ...
After Lupin, Ajantha Pharma too launches generic ADHD drug in US A month after Lupin got it, Ajanta Pharma too said it got the approval to launch a generic version of Concordia Pharmaceuticals Inc.’s ADHD drug Kapvay. Lupin had got the nod in October, and said the drug had sales of around $66 mln in the US. Ajantha Pharma also said it ha...